WallStreetZenWallStreetZen

NASDAQ: SVRA
Savara Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SVRA stock forecasts and price targets.

Forecast return on equity

Is SVRA forecast to generate an efficient return?

Company
88.26%
Industry
19.69%
Market
167.82%
SVRA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SVRA forecast to generate an efficient return on assets?

Company
65.99%
Industry
23.76%
SVRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SVRA earnings per share forecast

What is SVRA's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.62
Avg 2 year Forecast
-$0.39
Avg 3 year Forecast
-$0.00

SVRA revenue forecast

What is SVRA's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$2.1M
Avg 2 year Forecast
$71.7M
Avg 3 year Forecast
$169.8M

SVRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SVRA$5.42N/AN/A
ODTX$23.22$35.75+53.96%Strong Buy
JBIO$17.14$51.20+198.72%Strong Buy
OBX$17.50N/AN/ABuy
MNKD$3.58$8.25+130.45%Buy
View Top Biotech Stocks

Savara Stock Forecast FAQ

What is SVRA's earnings growth forecast for 2026-2028?

(NASDAQ: SVRA) Savara's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.18%.

Savara's earnings in 2026 is -$139,309,000.On average, 10 Wall Street analysts forecast SVRA's earnings for 2026 to be -$126,933,197, with the lowest SVRA earnings forecast at -$128,864,521, and the highest SVRA earnings forecast at -$120,810,489. On average, 10 Wall Street analysts forecast SVRA's earnings for 2027 to be -$80,540,326, with the lowest SVRA earnings forecast at -$116,783,473, and the highest SVRA earnings forecast at -$47,461,263.

In 2028, SVRA is forecast to generate -$410,920 in earnings, with the lowest earnings forecast at -$20,135,081 and the highest earnings forecast at $38,831,943.

If you're new to stock investing, here's how to buy Savara stock.

What is SVRA's revenue growth forecast for 2026-2028?

(NASDAQ: SVRA) Savara's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.

Savara's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast SVRA's revenue for 2026 to be $422,220,331, with the lowest SVRA revenue forecast at $0, and the highest SVRA revenue forecast at $1,337,544,698. On average, 10 Wall Street analysts forecast SVRA's revenue for 2027 to be $14,730,250,315, with the lowest SVRA revenue forecast at $9,584,298,780, and the highest SVRA revenue forecast at $19,217,497,043.

In 2028, SVRA is forecast to generate $34,893,274,347 in revenue, with the lowest revenue forecast at $28,671,945,093 and the highest revenue forecast at $44,186,230,826.

What is SVRA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SVRA) forecast ROA is 65.99%, which is higher than the forecast US Biotechnology industry average of 23.76%.

What is SVRA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SVRA) Savara's current Earnings Per Share (EPS) is -$0.58. On average, analysts forecast that SVRA's EPS will be -$0.62 for 2026, with the lowest EPS forecast at -$0.63, and the highest EPS forecast at -$0.59. On average, analysts forecast that SVRA's EPS will be -$0.39 for 2027, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.23. In 2028, SVRA's EPS is forecast to hit -$0.00 (min: -$0.10, max: $0.19).

What is SVRA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SVRA) forecast ROE is 88.26%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.